A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation® technology, which is used by biopharmaceutical companies in the complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 34M | 39M | 41M | 44M | 34M | 26M |
| Net Income | -46M | -41M | -38M | -24M | -19M | -12M |
| EPS | $-0.43 | $-0.39 | $-0.37 | $-0.23 | $-0.21 | $-0.17 |
| Free Cash Flow | -41M | -29M | -25M | -33M | -15M | -11M |
| ROIC | -56.8% | -19.9% | -16.3% | -9.3% | -7.3% | -35.4% |
| Gross Margin | 80.0% | 81.6% | 88.5% | 88.5% | 89.2% | 89.4% |
| Debt/Equity | 0.00 | 0.16 | 0.16 | 0.13 | 0.00 | 0.15 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | - | - |
| Operating Income | -54M | -51M | -48M | -27M | -18M | -11M |
| Operating Margin | -155.6% | -132.5% | -117.0% | -61.8% | -53.7% | -42.3% |
| ROE | -25.3% | -18.7% | -16.3% | -9.3% | -7.3% | -50.5% |
| Shares Outstanding | 107M | 105M | 102M | 102M | 91M | 70M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 22M | 26M | 34M | 44M | 41M | 39M | 34M |
| Gross Margin | 88.4% | 89.4% | 89.2% | 88.5% | 88.5% | 81.6% | 80.0% |
| R&D | 18M | 18M | 15M | 20M | 24M | 22M | 22M |
| SG&A | 5.6M | 7.4M | 19M | 26M | 30M | 30M | 30M |
| EBIT | -12M | -11M | -18M | -27M | -48M | -51M | -54M |
| Op. Margin | -57.4% | -42.3% | -53.7% | -61.8% | -117.0% | -132.5% | -155.6% |
| Net Income | -13M | -12M | -19M | -24M | -38M | -41M | -46M |
| Net Margin | -59.6% | -45.2% | -56.3% | -53.3% | -91.8% | -106.3% | -132.6% |
| Non-Recurring | -2K | -26K | 0 | 0 | 697K | 1.8M | 3.1M |
| Returns on Capital | |||||||
| ROIC | -94.8% | -35.4% | -7.3% | -9.3% | -16.3% | -19.9% | -56.8% |
| ROE | -99.6% | -50.5% | -7.3% | -9.3% | -16.3% | -18.7% | -25.3% |
| ROA | N/A | -45.7% | -6.7% | -8.2% | -14.1% | -16.2% | -21.4% |
| Cash Flow | |||||||
| Op. Cash Flow | -8.8M | -8.8M | -11M | -15M | -22M | -28M | -40M |
| Free Cash Flow | -10M | -11M | -15M | -33M | -25M | -29M | -41M |
| Owner Earnings | -11M | -12M | -20M | -29M | -40M | -45M | -56M |
| CapEx | 1.3M | 2.1M | 3.8M | 18M | 3.7M | 1.7M | 1.7M |
| Maint. CapEx | 614K | 1.0M | 1.4M | 2.7M | 4.2M | 4.3M | 4.3M |
| Growth CapEx | 658K | 1.0M | 2.4M | 16M | 0 | 0 | 0 |
| D&A | 614K | 1.0M | 1.4M | 2.7M | 4.2M | 4.3M | 4.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 1.8M | 2.5M | 8.0M | 12M | 14M | 13M | 12M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -18M | -30M | -255M | N/A | N/A | N/A | -106M |
| Cash & Equiv. | 15M | 19M | 48M | 11M | 47M | 28M | 106M |
| Long-Term Debt | N/A | 142K | 142K | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.36 | 0.15 | 0.00 | 0.13 | 0.16 | 0.16 | 0.00 |
| Interest Coverage | -239.3 | -509.5 | -43.2 | -5066.9 | N/A | N/A | N/A |
| Equity | 14M | 33M | 263M | 254M | 232M | 206M | 180M |
| Total Assets | -67K | 52M | 284M | 287M | 268M | 239M | 213M |
| Total Liabilities | 1.2M | 19M | 21M | 33M | 36M | 33M | 33M |
| Intangibles | 0 | N/A | N/A | 0 | 0 | 0 | 4.2M |
| Retained Earnings | N/A | -95M | -114M | -138M | -176M | -217M | -252M |
| Working Capital | N/A | 34M | 255M | 237M | 172M | 156M | 109M |
| Current Assets | -67K | 45M | 270M | 252M | 190M | 172M | 125M |
| Current Liabilities | N/A | 12M | 16M | 15M | 18M | 16M | 16M |
| Per Share Data | |||||||
| EPS | -0.23 | -0.17 | -0.21 | -0.23 | -0.37 | -0.39 | -0.43 |
| Owner EPS | -0.20 | -0.18 | -0.22 | -0.29 | -0.39 | -0.43 | -0.52 |
| Book Value | 0.24 | 0.48 | 2.89 | 2.48 | 2.27 | 1.96 | 1.69 |
| Cash Flow/Share | -0.16 | -0.13 | -0.12 | -0.14 | -0.21 | -0.26 | -0.39 |
| Dividends/Share | 0.00 | N/A | N/A | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 56.1M | 69.5M | 90.9M | 102.5M | 102.5M | 105.3M | 106.7M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -2.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 3.5 | N/A | N/A | N/A | 0.5 |
| Price/Sales | N/A | N/A | 33.7 | N/A | N/A | N/A | 2.7 |
| FCF Yield | N/A | N/A | -1.6% | N/A | N/A | N/A | -43.8% |
| Market Cap | 0 | N/A | 917M | 0 | 0 | 0 | 94M |
| Avg. Price | 0.00 | N/A | 12.57 | 0.00 | 0.00 | 0.00 | 0.88 |
| Year-End Price | 0.00 | N/A | 10.09 | 0.00 | 0.00 | 0.00 | 0.88 |
MAXCYTE, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 87.5%.
MAXCYTE, INC. (MXCT) has a 5-year average return on invested capital (ROIC) of -17.6%. This is below average and may indicate limited pricing power.
MAXCYTE, INC. (MXCT) has a market capitalization of $94M. It is classified as a small-cap stock.
MAXCYTE, INC. (MXCT) does not currently pay a regular dividend.
MAXCYTE, INC. (MXCT) operates in the Services-Commercial Physical & Biological Research industry, within the Industrials sector.
MAXCYTE, INC. (MXCT) reported annual revenue of $39 million in its most recent fiscal year, based on SEC EDGAR filings.
MAXCYTE, INC. (MXCT) has a net profit margin of -106.3%. The company is currently unprofitable.
MAXCYTE, INC. (MXCT) generated $-29 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
MAXCYTE, INC. (MXCT) has a debt-to-equity ratio of 0.16. This indicates a conservatively financed balance sheet.
MAXCYTE, INC. (MXCT) reported earnings per share (EPS) of $-0.39 in its most recent fiscal year.
MAXCYTE, INC. (MXCT) has a return on equity (ROE) of -18.7%. A negative ROE may indicate losses or negative equity.
MAXCYTE, INC. (MXCT) has a 5-year average gross margin of 87.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for MAXCYTE, INC. (MXCT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MAXCYTE, INC. (MXCT) has a book value per share of $1.96, based on its most recent annual SEC filing.